ArticleScientific reports2025
A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of bisphosphonates on cardiac arrhythmia has always been controversial. We aimed to evaluate the risk of bisphosphonates (BPs) on arrhythmia and to characterize the main features of BP-induced arrhythmia by data mining the FDA adverse event Reporting System (FAERS). From the first quarter of 2016 to the second quarter of 2022, reports for BP-related cardiac arrhythmia adverse event (AE) from FAERS database were analyzed in this study. The reporting odds ratio (ROR) and information components (IC) were used to identify disproportionate reporting of BP-related cardiac arrhythmias. We identified a total of 2377 BP-related cardiac arrhythmias cases which appeared to influence more women (61.88%) than men (28.02%), with a median age of 70 (interquartile range [IQR] 59-78) years. Compared with the full database, BPs were detected with pharmacovigilance of cardiac arrhythmias (ROR025 = 1.43, [1.39-1.47]). All studied bisphosphonates except ibandronate sodium and clodronate disodium were correlated with the reporting frequency of cardiac arrhythmia (HLGT), with ROR ranging from 1.28 with pamidronate disodium to 11.08 with etidronate disodium. The spectrum of arrhythmias induced by BPs differed among therapeutic regimens. There were significant differences in the onset time among BP regimens. Bisphosphonates use is associated with adverse cardiac arrhythmias, with the exception of ibandronate sodium and clodronate disodium. Our data support differential effects of BPs on cardiac arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.